Positive press release – Publication highlights the safety and potential benefits of re-dosing Diamyd

A new study published in the International Journal of Molecular Sciences shows that re-dosing Diamyd® is safe and potentially effective in preserving insulin production in individuals with type 1 diabetes.

The study, led by Professor Johnny Ludvigsson at Linköping University, included six participants with the HLA DR3-DQ2 haplotype who had previously participated in DIAGNODE-1 or DIAGNODE-2. The participants received a fourth or fifth intralymphatic dose of Diamyd® in combination with vitamin D.

After 12 months of follow-up, stabilized endogenous insulin production, improved blood sugar control, and reduced insulin requirements were observed, without any serious side effects. Immunological markers also indicated maintained immunomodulation.

These results support the continued development of Diamyd® as a precision medicine treatment for type 1 diabetes.